Symptom-Based Opioid Dosing Shortens Hospital Stay in Neonatal Opioid Withdrawal Syndrome

Emerging data published in JAMA reveals that a symptom-based opioid dosing strategy significantly reduced time to medical readiness for discharge in infants with neonatal opioid withdrawal syndrome (NOWS) compared with traditional scheduled opioid tapering.¹ The research found infants who were treated with symptom-based dosing were ready for discharge about 2.3 days earlier than expected, with no increase in short-term safety risks.

NOWS and Pharmacologic Management

1 infant is diagnosed every 27 minutes in the United States with NOWS according to JAMA, emphasizing just one of the rising consequences of the ongoing opioid epidemic.¹ NOWS is a result due to utero opioid exposure and presents itself through several withdrawal symptoms such as irritability, feeding difficulty, and autonomic instability following birth.²

The initial management for NOWS utilizes nonpharmacologic approaches rooming-in, swaddling, and breastfeeding support.³ In event these measures are insufficient, pharmacologic treatment which implements opioids—such as morphine or methadone—is necessitated.^2,4

Traditionally, clinical practice has treatment rely on a scheduled opioid taper approach where infants receive escalating doses followed by gradual weaning off. An alternative method is opioids are only administered when withdrawal symptoms reach a defined threshold, aligning treatment intensity with clinical need.¹ This emerging alternative approach has gained recognition alongside the Eat, Sleep, Console (ESC) model, which prioritizes functional assessment of infant well-being rather than symptom scoring to guide management decisions.³

Study Design

The OPTimize NOW trial (NCT05980260)⁵, which had its findings published in JAMA, was a multicenter, cluster randomized crossover study that was conducted across 23 US hospitals. Research consisted of 626 infants with 383 infants included in the primary ESC-based analysis. Infants deemed eligible were at least 6 weeks’ gestation and had documented prenatal opioid exposure.^1,5

Implementation of either symptom-based dosing followed by scheduled tapering or the reverse sequence were randomized in the trial. The administration of opioids included agents such as morphine, methadone, or buprenorphine, and were guided by site-specific protocols consistent with current standards of care.¹

The data measured time from birth to medical readiness for discharge, with secondary outcomes including length of stay, need for pharmacologic treatment, and safety measures.

Key Findings

Amongst infants that were managed with ESC approach, data revealed symptom-based dosing led to a significant reduction in time to medical readiness for discharge compared with scheduled tapering (9.18 vs 11.61 days; adjusted mean ratio, 0.79; 95% CI, 0.65-0.96).¹

No significant differences were noted between groups in the initiation of pharmacologic treatment, overall length of hospital stay, or safety outcomes through 3 months of age.¹

Approximately 35% of infants in the symptom-based group ultimately required transition to scheduled opioid dosing due to persistent withdrawal symptoms, highlighting a need for individualized escalation in particular cases.¹

Clinical Implications

Symptom-based dosing may reduce cumulative opioid exposure, aligning with broader efforts to minimize opioid use while maintaining effective symptom control.⁶ Practitioners are suited to ensure appropriate dosing thresholds, monitoring for withdrawal severity, and preventing oversedation.

Shorter time to medical readiness for discharge may also translate into reduced hospital resource utilization and overall healthcare costs. Fewer inpatient days can decrease the need for nursing care, monitoring, medication administration, and ancillary services. Earlier stabilization may also improve bed availability in neonatal units, allowing hospitals to allocate resources more efficiently.

Understanding that a subset of patients will still require escalation to scheduled regimens despite effectiveness of symptom-based dosing is crucial. This data highlights a need for flexible, patient-specific treatment plans and close interdisciplinary collaboration.

REFERENCES

1. Devlin LA, Babineau DC, Merhar SL, et al. Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial. JAMA. Published online April 25, 2026. doi:10.1001/jama.2026.5782

2. Hudak ML, Tan RC; COMMITTEE ON DRUGS; COMMITTEE ON FETUS AND NEWBORN; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-e560. doi:10.1542/peds.2011-3212

3. Young LW, Ounpraseuth ST, Merhar SL, et al. Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal. New England Journal of Medicine. 2023;388(25). doi:10.1056/nejmoa2214470

4. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;134(2):e547-e561. doi:10.1542/peds.2013-3524

5. Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach (OPTimize NOW). ClinicalTrials.gov identifier: NCT05980260. Updated February 27, 2026. Accessed April 29, 2026. https://clinicaltrials.gov/study/NCT05980260

6. Patrick SW, Schumacher RE, Horbar JD, et al. Improving Care for Neonatal Abstinence Syndrome. Pediatrics. 2016;137(5):e20153835. doi:10.1542/peds.2015-3835

‌